Literature DB >> 29267893

Crossover is not associated with faster trial accrual.

E Y Chen1, V Prasad2.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29267893     DOI： 10.1093/annonc/mdx793

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration.

Authors:  Talal Hilal; Miguel Gonzalez-Velez; Vinay Prasad
Journal:  JAMA Intern Med       Date:  2020-08-01       Impact factor: 21.873

2.  What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020).

Authors:  Kristina Jenei; Alyson Haslam; Timothée Olivier; Milos Miljkovíc; Vinay Prasad
Journal:  BMJ Open       Date:  2022-10-07       Impact factor: 3.006

3.  When is crossover desirable in cancer drug trials and when is it problematic?

Authors:  A Haslam; V Prasad
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 51.769
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.